New Milford, NJ, United States of America

Hetalben Prajapati

This inventor holds 1 USPTO granted patent. Top assignee: Abon Pharmaceuticals LLC. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hetalben Prajapati. Retrieved from https://idiyas.com/inventor/hetalben-prajapati

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hetalben Prajapati and Long-Acting Injectable Formulations.

Introduction

Hetalben Prajapati is an inventor associated with New Milford, New Jersey, and Abon Pharmaceuticals LLC. Her patent work includes a formulation designed to provide extended release of a poorly water-soluble active pharmaceutical ingredient.

Latest Patents

Prajapati is associated with 1 patent, titled “Long Acting Injectable Formulations.” The invention describes an extended-release formulation containing a poorly water-soluble active pharmaceutical ingredient dispersed as discrete particles, with a particle size of about 0.5 to 25 micrometers. It combines a non-aqueous liquid vehicle—based on a hydrophobic lipid, selected hydrophilic organic compounds, or a combination of these—with an amphiphilic agent. The formulation is described as non-gelling and thixotropic, with a viscosity below 10 poise at a shear rate of 10 per second and a temperature of 25°C.

Career Highlights

Prajapati’s listed patent reflects work on injectable drug-delivery formulations, particularly approaches intended to extend the release of poorly water-soluble pharmaceutical ingredients. The available information identifies Abon Pharmaceuticals LLC as her company.

Collaborations

Yanming Zu is identified as a coworker. The provided information does not specify her role in the patent or the nature of their collaboration.

Conclusion

Hetalben Prajapati’s patent on long-acting injectable formulations focuses on a non-aqueous, thixotropic delivery system intended to support extended release of a poorly water-soluble active ingredient.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…